Form 4: Delcath Systems Director Elizabeth Czerepak Granted Stock Options

Director Elizabeth Czerepak received stock options to purchase 22,500 shares of Delcath Systems common stock.

Summary

• Elizabeth Czerepak, a director of Delcath Systems, Inc., was granted stock options on May 23, 2024.
• The options allow her to purchase 22,500 shares of Delcath Systems common stock at an exercise price of $7.85 per share.
• The options vest monthly over a year, starting May 23, 2024, as long as she remains a director.
• The options expire 10 years from the grant date or two years after her last day of service, whichever is earlier.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The granting of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Gilead Sciences, Amgen, and Biogen routinely use stock options to incentivize their board members.
• The vesting schedule of one-twelfth per month is a fairly standard vesting schedule.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates